ArticleCardiovascular diabetology2009
Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes - a two year follow-up of 243 patients.
Article in Cardiovascular diabetology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D-PATH study).Journal of diabetes investigation · 2026Trial
- A local-saturation-and-delay MRI method for evaluation of red blood cells aggregationFrontiers in bioengineering and biotechnology · 2023Article
- WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort study.ESC heart failure · 2021Article
- Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism.Diabetic medicine : a journal of the British Diabetic Association · 2021Article
- Impact of diabetes in patients waiting for invasive cardiac procedures during COVID-19 pandemic.Cardiovascular diabetology · 2021Article
- Clinically feasible method for assessing leukocyte rheology in whole blood.Heart and vessels · 2020Article
- Coagulatory Defects in Type-1 and Type-2 Diabetes.International journal of molecular sciences · 2019Review
- Article
- Treadmill exercise alleviates diabetic cardiomyopathy by suppressing plasminogen activator inhibitor expression and enhancing eNOS in streptozotocin-induced male diabetic rats.Endocrine connections · 2018Article
- Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk.Cardiovascular diabetology · 2015Article
- Impact of sleeve gastrectomy on red blood cell aggregation: a 12-month follow-up study.International journal of obesity (2005) · 2014Article
- Association of fibrinogen with severity of stable coronary artery disease in patients with type 2 diabetic mellitus.Disease markers · 2014Article
- Depletion of circulating blood NOS3 increases severity of myocardial infarction and left ventricular dysfunction.Basic research in cardiology · 2014Article
- Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study.Cardiovascular diabetology · 2012Article
- Characterization of macro-and microvascular function and structure in patients with type 2 diabetes mellitus.American journal of cardiovascular disease · 2011Article
- Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus.Cardiovascular diabetology · 2010Article
- Fibrinogen and associated risk factors in a high-risk population: urban Indigenous Australians, the DRUID Study.Cardiovascular diabetology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThrombosis is regarded to be a key factor in the development of acute coronary syndromes in patients with coronary artery disease (CAD). We hypothesize, that hemostatic and rheological risk factors may be of major relevance for the incidence and the risk stratification of these patients.
methodsIn 243 patients with coronary artery disease and stable angina pectoris parameters of metabolism, hemostasis, blood rheology and endogenous fibrinolysis were assessed. Patients were prospectively followed for 2 years in respect to elective revascularizations and acute coronary syndromes.
resultsDuring follow-up 88 patients presented with cardiac events, 22 of those were admitted to the hospital because of acute events, 5 Patients were excluded due to non- cardiac death. Patients with clinical events were found to be more frequently diabetic and presented with a more progressed coronary atherosclerosis. Even though patients with diabetes mellitus demonstrated a comparable level of multivessel disease (71% vs. 70%) the rate of elective revascularization was higher (41% vs. 28%, p < 0.05). The results were also unfavorable for the incidence of acute cardiovascular events (18% vs. 8%, p < 0.01). In comparison to non-diabetic patients diabetics demonstrated significantly elevated levels of fibrinogen (352 +/- 76 vs. 312 +/- 64 mg/dl, p < 0.01), plasma viscosity (1.38 +/- 0.23 vs. 1.31 +/- 0.16 mPas, p < 0.01), red blood cell aggregation (13.2 +/- 2.5 vs. 12.1 +/- 3.1 E, p < 0.05) and plasmin-activator-inhibitor (6.11 +/- 3.4 vs. 4.7 +/- 2.7 U/l, p < 0.05).
conclusionPathological alterations of fibrinogen, blood rheology and plasminogen-activator-inhibitor as indicators of a procoagulant state are of major relevance for the short-term incidence of cardiac events, especially in patients with diabetes mellitus type 2, and may be used to stratify patients to specific therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.